Free Trial

MetLife (NYSE:MET) Price Target Lowered to $95.00 at Keefe, Bruyette & Woods

MetLife logo with Finance background

MetLife (NYSE:MET - Free Report) had its price objective decreased by Keefe, Bruyette & Woods from $98.00 to $95.00 in a research note released on Wednesday morning,Benzinga reports. Keefe, Bruyette & Woods currently has an outperform rating on the financial services provider's stock.

MET has been the topic of several other research reports. Cowen reissued a "buy" rating on shares of MetLife in a report on Friday, March 7th. BMO Capital Markets initiated coverage on shares of MetLife in a research note on Thursday, January 23rd. They set a "market perform" rating and a $97.00 price objective for the company. JPMorgan Chase & Co. reduced their price target on MetLife from $88.00 to $86.00 and set an "overweight" rating on the stock in a report on Wednesday, April 2nd. Barclays lowered their price objective on shares of MetLife from $96.00 to $95.00 and set an "overweight" rating for the company in a research report on Friday, February 7th. Finally, Wells Fargo & Company boosted their price objective on shares of MetLife from $92.00 to $97.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $92.46.

View Our Latest Report on MET

MetLife Stock Up 2.1 %

MET stock traded up $1.49 during midday trading on Wednesday, hitting $72.89. The stock had a trading volume of 1,049,827 shares, compared to its average volume of 3,394,889. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.16 and a quick ratio of 0.16. The business has a 50-day moving average of $80.32 and a two-hundred day moving average of $82.46. MetLife has a 52-week low of $65.21 and a 52-week high of $89.05. The firm has a market cap of $49.65 billion, a price-to-earnings ratio of 12.21, a price-to-earnings-growth ratio of 0.65 and a beta of 0.89.

MetLife (NYSE:MET - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The financial services provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.13 by ($0.05). MetLife had a net margin of 6.19% and a return on equity of 20.42%. As a group, equities research analysts forecast that MetLife will post 9.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MetLife

Institutional investors have recently added to or reduced their stakes in the stock. United Asset Strategies Inc. increased its stake in MetLife by 1.1% in the 4th quarter. United Asset Strategies Inc. now owns 10,933 shares of the financial services provider's stock valued at $895,000 after buying an additional 120 shares during the period. Barrett & Company Inc. boosted its holdings in MetLife by 1.0% in the 4th quarter. Barrett & Company Inc. now owns 11,942 shares of the financial services provider's stock valued at $978,000 after purchasing an additional 121 shares in the last quarter. Eagle Strategies LLC increased its position in MetLife by 4.8% during the 4th quarter. Eagle Strategies LLC now owns 2,707 shares of the financial services provider's stock worth $222,000 after purchasing an additional 123 shares during the period. J.W. Cole Advisors Inc. raised its stake in shares of MetLife by 2.1% during the 4th quarter. J.W. Cole Advisors Inc. now owns 6,044 shares of the financial services provider's stock worth $495,000 after buying an additional 126 shares in the last quarter. Finally, Davis R M Inc. grew its holdings in MetLife by 4.2% during the fourth quarter. Davis R M Inc. now owns 3,148 shares of the financial services provider's stock worth $258,000 after acquiring an additional 127 shares during the period. Institutional investors and hedge funds own 94.99% of the company's stock.

MetLife Company Profile

(Get Free Report)

MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.

Featured Stories

Analyst Recommendations for MetLife (NYSE:MET)

Should You Invest $1,000 in MetLife Right Now?

Before you consider MetLife, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.

While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Make Your Money Work Harder: The Power of Dividend Investing
7 Cybersecurity Stocks Outperforming the Market Right Now
Markets in Rally Mode: Will Earnings Keep It Going?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines